December 13, 2016 : DCMS #323

DISASTERS AVERTED — Near Miss Case Studies

The 5 Rights of Medication Administration

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

Dr. Jeffrey Mechanick Part 7, Government Assistance

HOMERUN SLIDES — Great Clinical Presentation Highlights

EMPA-REG Outcome Trial, Part 1

CLINICAL GEMS — The Best from Diabetes Texts

International Textbook of Diabetes Mellitus, 4th Ed., Excerpt #54: Incretin Physiology in Health and Disease Part 4 of 6

MOST POPULAR ARTICLES OF THE MONTH

#1 Implantable CGMS Submitted to FDA
#2 Towards a Game-Changing Type 1 Diabetes Vaccine
#3 FDA Approves 2 New Diabetes Combos

A few years ago Dr. Steven Nissen turned the diabetes world upside down when he went on a crusade to get TZD’s off the market due to cardiovascular risk. One of the results of his efforts was the FDA’s requirement that all new diabetes drugs would have extensive cardiovascular testing, which could potentially add years to the approval time. When the SGLT-2 Inhibitors were approved they all had to have these studies. One of these novel compounds had an effect that no one would have expected. It improved cardiovascular outcomes.

The EMPA-REG OUTCOME study showed how this was possible, and this week our Homerun Slides focus on this trial.

Dave Joffe

Editor-in-chief

Male, 56 years of age, type 2 dm, hypertension with orthostatic hypotension, peripheral neuropathy, hyperlipidemia, class II obesity. He fills his pill box every month and has been doing so for years. It has taken some time, but we finally came up with a plan with his meds and lifestyle where he has been feeling very well and his numbers are better than ever.

He filled his med box a week before contacting me. He wasn’t feeling well. Feeling dizzy and his legs were feeling like rubber.

Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 7 of this Exclusive Interview, Dr. Mechanick shares his thoughts on what healthcare professionals should do to affect change in government legislation.

In this week’s Homerun Slides: EMPA-REG Outcome Trial Part 1: Meta-analysis of intensive glucose control in T2DM.

Central nervous effects: A role for GLP-1 in the central nervous regulation of food intake has been inferred from the high density of GLP-1 receptors in the hypothalamus. Also, direct intracerebroventricular administration of GLP-1 has caused a significant reduction in food intake in rats, and these actions could be abolished by co-administration of the GLP-1 receptor antagonist exendin.

Premarket Approval application submitted for Eversense® CGM system.

In part 3 of this exclusive interview, Dr. Faustman discusses how a cure based on the inexpensive BCG vaccine could permanently change type 1 treatment, and whether results could also apply to type 2.

IDegLira, LixiLan go head-to-head; FDA approves Novo Nordisk’s Xultophy and Sanofi’s Soliqua on the same day.